FDA's approval of GlaxoSmithKline PLC's Nucala is a big step toward recognition of a severe asthma phenotype characterized by elevated eosinophils, but the agency chose to defer to the medical community on the task of how to use the biomarker to identify patients.
"Consensus on defining patients based on an eosinophilic characteristic has been challenging," Office of Drug Evaluation II Deputy Director Mary